单药替莫唑胺治疗转移性肛管直肠恶性黑色素瘤的长期缓解
Prolonged Remission in Metastatic Ano-Rectal Malignant Melanoma With Single Agent Temozolomide.
作者信息
Swamy Anusha Mruthyunjaya, Sundriyal Deepak, Kapoor Mayank, Khanna Mridul, Phulware Ravi Hari, Jandrasupalli Kranthi Kumar, Shriwastav Ujjawal, Sehrawat Amit
机构信息
Department of Medical Oncology, Hematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
出版信息
Cancer Rep (Hoboken). 2025 Jan;8(1):e70121. doi: 10.1002/cnr2.70121.
INTRODUCTION
With the use of immune checkpoint inhibitors (ICIs) and targeted therapies, the clinical outcomes of metastatic melanoma have drastically improved. The current scenario has reduced the use of chemotherapy as a first-line treatment. We report an interesting case of a patient with stage IV ano-rectal canal malignant melanoma with an exceptional response to single-agent temozolomide.
CASE REPORT
We diagnosed a 55-year-old female with stage IV anorectal melanoma, BRAF V600 mutation negative. Owing to her poor performance status (PS) and non-affordability of immunotherapy, after informed decision-making, she was started on single agent, temozolomide. She achieved a complete metabolic response and sustained it for 3 years and continues to do so with the first-line single-agent temozolomide.
CONCLUSION
In a resource-limited setting, where access to ICIs and targeted therapies is not feasible, and in patients who fail to tolerate these therapies, oral chemotherapy continues to remain effective and is worth trying in patients with poor PS.
引言
随着免疫检查点抑制剂（ICI）和靶向治疗的应用，转移性黑色素瘤的临床疗效有了显著改善。目前的情况减少了化疗作为一线治疗的使用。我们报告了一例有趣的病例，一名IV期肛管恶性黑色素瘤患者对单药替莫唑胺有异常反应。
病例报告
我们诊断出一名55岁女性患有IV期肛管黑色素瘤，BRAF V600突变阴性。由于她的体能状态（PS）较差且无法负担免疫治疗费用，在经过知情决策后，她开始接受单药替莫唑胺治疗。她实现了完全代谢缓解，并持续了3年，目前仍在使用一线单药替莫唑胺维持缓解。
结论
在资源有限的情况下，无法使用ICI和靶向治疗，以及无法耐受这些治疗的患者中，口服化疗仍然有效，对于PS较差的患者值得一试。
Zotero 插件